New Diagnostic Biomarker Test Shows Promise in Monitoring Ovarian Cancer
... vice president, research and development, Abbott Diagnostics. "HE4 represents an important advancement in monitoring these pelvic masses."
Diagnostics, Inc. and Abbott have signed a license agreement to develop this new ovarian cancer marker for use on Abbott's automated ARCHITECT(R) diag...
Fujirebio Diagnostics Appoints Grady Barnes as Chief Scientific Officer
... MALVERN, Pa., March 23 /PRNewswire/ -- fujirebio
Diagnostics, Inc., the premier cancer diagnostics ... as Chief Scientific Officer. Dr. Barnes comes to fujirebio
Diagnostics with 25 years of diagnostics experienc...product candidates and licensing opportunities for fujirebio
"Dr. Barnes' extensiv...
Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer
... the biomarkers HE4 and CA125 along with ROMA, the fujirebio
Diagnostics test appears to be more sensitive than... 72 women will develop ovarian cancer.
Diagnostics is the premier cancer diagnostics comp...
Fujirebio Diagnostics and Abbott Agree To Develop New Ovarian Cancer Test for Abbott's Architect(R) Analyzers
...Pa. and Abbott Park, Ill., Jan. 27 /PRNewswire/ -- fujirebio
Diagnostics, Inc. and Abbott have signed a license...TECT(R) diagnostic analyzers. Under the agreement, fujirebio
Diagnostics will develop and manufacture for Abbot...h.D., vice president and chief scientific officer, fujirebio
Diagnostics. "The HE4 test, which is expected to b...
Fujirebio Diagnostics and Roche Diagnostics Sign Agreement for New Ovarian Cancer Test
Diagnostics' HE4 Test will be Available Through Ro... Pa. and Basel, SwitzerlandDec. 16 /PRNewswire/ -- fujirebio
Diagnostics, Inc. and Roche Diagnostics announced ...reement, Roche will develop an assay kit utilizing fujirebio
Diagnostics' HE4 test on its automated immunoassay...
Vascular Solutions CEO Elected to MDMA Board of Directors
...f Alta Partners; Jo Ellen Slurzberg of Almyra, Inc.; Mark Sieczkerek
of Conceptus, Inc.; Thomas Thompson of Neuro Resource Group (NRG); Paul
Touhey of fujirebio
Diagnostics, Inc.; Russ Trenary of Advanced Medical
Optics (AMO) and Mark Wan of Three Arch Partners.
As founder of Vascular Solutions in 1997, Root...
Malignant tumor or benign cyst?
...on, vice president and chief scientific officer of fujirebio
Diagnostics, the developers of the CA 125 test. As...eventually lead to a plausible screening tool.
Diagnostics has developed a manual test for HE4 an...ll be developing automated formats of the test for fujirebio
instruments. The HE4 test is CE marked in Europe. ...
BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management
Alliance Aims to First Develop Powerful Tools for Detecting Ovarian Cancer Earlier
FRANKLIN LAKES, N.J. and MALVERN, Pa., May 4 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) and Fujirebio
Diagnostics, Inc., announced today the signing of a worldwide development ...
Fujirebio Diagnostics Named One of the Best Places to Work in Pennsylvania
MALVERN, Pa., Oct. 6 /PRNewswire/ -- fujirebio
Diagnostics, Inc., a
Malvern-based company, was re...e state's economy, its workforce and businesses.
Diagnostics, the premier cancer diagnostics compan...marker assays, employs 125 people in
Diagnostics specializes in the clinical